Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Long-Term Deferred Tax: 2018-2025

  • China SXT Pharmaceuticals' Long-Term Deferred Tax fell 14.59% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year decrease of 14.59%. This contributed to the annual value of -$1.4 million for FY2025, which is 15.34% down from last year.
  • China SXT Pharmaceuticals' Long-Term Deferred Tax amounted to -$1.5 million in Q3 2025, which was down 2.01% from -$1.4 million recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $321,444 in Q1 2021 and a low of -$1.5 million during Q3 2025.
  • In the last 3 years, China SXT Pharmaceuticals' Long-Term Deferred Tax had a median value of -$1.3 million in 2024 and averaged -$1.2 million.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Long-Term Deferred Tax spiked by 184.87% in 2021, and later tumbled by 42.58% in 2024.
  • China SXT Pharmaceuticals' Long-Term Deferred Tax (Quarterly) stood at $321,444 in 2021, then reached -$962,152 in 2023, then tumbled by 33.41% to -$1.3 million in 2024, then dropped by 14.59% to -$1.5 million in 2025.
  • Its Long-Term Deferred Tax stands at -$1.5 million for Q3 2025, versus -$1.4 million for Q1 2025 and -$1.3 million for Q3 2024.